Company Reports

Sonic Healthcare provides laboratory medicine/pathology and diagnostic imaging radiology. It is the third-largest private provider of laboratory medicine globally, behind Quest Diagnostics and Labcorp. Strategy focuses on being a low-cost provider and gaining cost advantage over competitors through scale. This has mostly been pursued through acquisitions, buying smaller operators to expand its market share in geographies where it operates. The firm emphasizes medical leadership, recognizing referring doctors as the primary customer, focusing on improving their experience and efficiency.

Sonic posted an 11% lift in fiscal 2026 underlying EBITDA to AUD 1.933 billion, with a slightly lower constant-currency amount comfortably within the guidance range. Fiscal 2027 EBITDA guidance has been set at AUD 1.95 billion-AUD 2.03 billion at constant currency. Shares fell almost 10% on Aug. 20.

Ahead of Sonic Healthcare's fiscal 2026 results release in August, we highlight key areas of focus. Critically, we reassess their implications for our longer-term earnings assumptions and retest our key investment thesis on the multinational pathology and Australian radiology group.

Sonic Healthcare provides laboratory medicine/pathology and diagnostic imaging radiology. It is the third-largest private provider of laboratory medicine globally, behind Quest Diagnostics and Labcorp. Strategy focuses on being a low-cost provider and gaining cost advantage over competitors through scale. This has largely been pursued through acquisitions, buying smaller operators to expand its market share in geographies where it operates. The firm emphasizes medical leadership, recognizing referring doctors as the primary customer, focusing on improving their experience and efficiency.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

We transfer coverage of Sonic Healthcare, a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second largest in Belgium and New Zealand, and third in the US. Sonic is also the second-largest Australian player in diagnostic imaging.

Sonic's interim 2026 EBITDA rose 10% on 5% organic sales growth and underlying EBITDA margins up 30 basis points to 18%. Full-year EBITDA guidance of 8% growth at the midpoint in constant-currency was reaffirmed, and guided depreciation and interest expense was modestly lowered. Shares rallied 10%.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Sonic Healthcare reaffirmed fiscal 2026 EBITDA guidance of 8% growth at the midpoint in constant currency terms, with solid organic sales growth of 5% year to date. Management also guides to modestly lower fiscal 2026 depreciation and interest expense. Shares reacted positively, up 6%.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Sonic Healthcare's fiscal 2025 EBITDA rose 9% on 5% organic sales growth and underlying EBITDA margins expanding 40 basis points to 18%. Fiscal 2026 EBITDA guidance implies 8% growth at the midpoint in constant-currency, disappointing the market with shares down over 12%.

Medicare Australia statistics for benefits paid in core pathology and diagnostic imaging for the five months to May 2025 increased by 5% and 7%, respectively, on the previous corresponding period, key revenue drivers for Sonic Healthcare, Integral Diagnostics, and Australian Clinical Labs.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Narrow-moat Sonic reported interim 2025 EBITDA growth of 12% to AUD 827 million on 6% organic revenue growth and underlying EBITDA margins expanding roughly 90 basis points to 18%. The result was driven by creditable cost control and strong organic sales growth in Australia partially offset by relatively weaker performances in the US and Germany. Sonic reiterated full-year underlying EBITDA guidance of AUD 1.70 billion-AUD 1.75 billion, implying 8% growth at the midpoint on fiscal 2024, and compares to our largely unchanged fiscal 2025 EBITDA forecast of AUD 1.72 billion. Our long-term estimates are also broadly unchanged, including our midcycle EBITDA margin forecast of 22%.

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Narrow-moat Sonic is acquiring Laboratory Group Dr. Kramer & Colleagues, primarily a pathology business in Germany, for EUR 423 million. Roughly half of the purchase price will be funded from scrip and the rest from existing cash. The deal is expected to close in the second half of fiscal 2025 and is subject to closing conditions, but we credit a three-month earnings contribution in fiscal 2025.

Narrow-moat Sonic reported constant-currency revenue and EBITDA growth of roughly 10% for the first four months of fiscal 2025, both meeting our expectations. Sonic reiterated fiscal 2025 EBITDA guidance of AUD 1.70 to AUD 1.75 billion, implying 8% growth at the midpoint of fiscal 2024, and compares with our unchanged fiscal 2024 EBITDA forecast of 1.74 billion. Our long-term estimates are also unchanged, including our midcycle EBITDA margin forecast of 22% compared with 19% in the second half of fiscal 2024.

Australian pathology market growth, measured by Medicare benefits paid excluding coronavirus testing, was up a strong 11% in first-quarter fiscal 2025. Demand for pathology is defensive and underpinned by population growth, aging demographics, higher incidence of diseases, wider adoption, and a higher number of tests available. In the long term, we expect margin expansion on increased operating leverage from higher volumes and improved labor productivity as digitization and newer artificial intelligence tools expedite diagnoses. We also expect average fee increases through stronger pricing, additional government funding, and favorable mix benefits. Shares in narrow-moat Sonic Healthcare are undervalued versus our unchanged AUD 32 fair value estimate, as well as in no-moat Healius.